CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study
CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH
Excerpt from the Press Release:
SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial in neurogenic orthostatic hypotension (nOH).
nOH is a serious condition characterized by a sudden drop in blood pressure when a person moves from sitting to standing, or from a supine position to sitting. This leads to debilitating dizziness, fainting, falls, hospitalizations and cognitive impairment due to reduced blood flow to the brain. Nearly 700,000 patients with Parkinson’s disease (PD) and related alpha-synuclein disorders, such as Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA) and Pure Autonomic Failure (PAF), are diagnosed with nOH in the U.S. Diagnosis of nOH is associated with higher morbidity and mortality among these patients.
CuraAX, given as an oral tablet, is a selective partial α1A-adrenergic receptor agonist that is also CNS-penetrant. It is designed to stabilize blood pressure and maintain cerebral blood flow.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?